GlobalData published new report on the Top 25 pharma companies

17 September 2018

GMP News

The performance highlights of the Top 25 publicly traded global pharmaceutical companies by Market Cap (Mcap) for the quarter ended June 30, 2018 (Q2), compared to the quarter ended March 31, 2018 (Q1), have been analyzed in the latest research from GlobalData, a leading data and analytics company.

The top 25 pharmaceutical companies collective Mcap reached around $2.7 tn, growing marginally at 1.1% in Q2 2018 with leading companies Merck US, Bayer, GSK, Eli Lilly, CSL and Shire achieving double digit Mcap growth during the same period.

J&J maintained its No.1 position in the Top 25 with Chinese pharmaceutical company, Jiangsu Hengrui Medicine, entering the list during the period.

Six of the top 25 companies experienced positive Mcap growth in Q2 2018, with CSL, Shire and Bayer achieving double digit growth rates of 24%, 20% and 16%, respectively.

The Mcap of BMS and Celgene declined over 10% in Q2 2018. Institutional investors in BMS traded a substantial amount of shares in the period which is thought to have impacted their Mcap performance while setbacks in some key pipeline drugs affected Celgene’s Mcap value.


There were plenty of new developments and market activity during Q2 2018, reflecting a growing trend among the big pharma companies to focus on their core business areas. BMS announced its intention to sell its French consumer health business, P&G acquired Merck KGaA’s vitamin brands; GSK bought the consumer healthcare joint venture from Novartis for $13bn and Pfizer announced plans to divest its European generic-drug business.


In geographical terms, North America contributed an aggregate Mcap of $1.5tn, with 13 companies from this region featuring in the top 25 list. The Mcap of European and Asia-Pacific (APAC) pharmaceutical companies grew 3.2% and 16.5% respectively during the period.


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more